Pulmonary hypertension in China: Pulmonary vascular disease: The global perspective

Zhenguo Zhai, Jun Wang, Lan Zhao, Jason Yuan, Chen Wang

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Significant progress has been made in understanding the pathogenesis of pulmonary hypertension (PH) and developing therapeutic approaches for PH in recent years. Most of the currently available data regarding the prevalence, diagnosis, treatment, and prognosis of PH are from American and European populations. Whether these data are also valid in the Chinese population is still controversial. China has a relatively large population of patients with PH for clinical and basic research. However, many medical centers and hospitals in China have limited experience with PH diagnosis and treatment. Given the potential higher prevalence of PH in China than in the United States and European countries, it is critical to develop suitable, effective, and novel therapeutic approaches for Chinese patients. Measures for the detection and prevention of PH need to be put in place urgently for the management of PH in China.

Original languageEnglish (US)
JournalChest
Volume137
Issue number6 SUPPL.
DOIs
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

Vascular Diseases
Pulmonary Hypertension
Lung Diseases
China
Population
Therapeutics
Research

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Pulmonary hypertension in China : Pulmonary vascular disease: The global perspective. / Zhai, Zhenguo; Wang, Jun; Zhao, Lan; Yuan, Jason; Wang, Chen.

In: Chest, Vol. 137, No. 6 SUPPL., 01.06.2010.

Research output: Contribution to journalArticle

Zhai, Zhenguo ; Wang, Jun ; Zhao, Lan ; Yuan, Jason ; Wang, Chen. / Pulmonary hypertension in China : Pulmonary vascular disease: The global perspective. In: Chest. 2010 ; Vol. 137, No. 6 SUPPL.
@article{644ad4db2239478c92277d4cd0e40902,
title = "Pulmonary hypertension in China: Pulmonary vascular disease: The global perspective",
abstract = "Significant progress has been made in understanding the pathogenesis of pulmonary hypertension (PH) and developing therapeutic approaches for PH in recent years. Most of the currently available data regarding the prevalence, diagnosis, treatment, and prognosis of PH are from American and European populations. Whether these data are also valid in the Chinese population is still controversial. China has a relatively large population of patients with PH for clinical and basic research. However, many medical centers and hospitals in China have limited experience with PH diagnosis and treatment. Given the potential higher prevalence of PH in China than in the United States and European countries, it is critical to develop suitable, effective, and novel therapeutic approaches for Chinese patients. Measures for the detection and prevention of PH need to be put in place urgently for the management of PH in China.",
author = "Zhenguo Zhai and Jun Wang and Lan Zhao and Jason Yuan and Chen Wang",
year = "2010",
month = "6",
day = "1",
doi = "10.1378/chest.09-2802",
language = "English (US)",
volume = "137",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Pulmonary hypertension in China

T2 - Pulmonary vascular disease: The global perspective

AU - Zhai, Zhenguo

AU - Wang, Jun

AU - Zhao, Lan

AU - Yuan, Jason

AU - Wang, Chen

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Significant progress has been made in understanding the pathogenesis of pulmonary hypertension (PH) and developing therapeutic approaches for PH in recent years. Most of the currently available data regarding the prevalence, diagnosis, treatment, and prognosis of PH are from American and European populations. Whether these data are also valid in the Chinese population is still controversial. China has a relatively large population of patients with PH for clinical and basic research. However, many medical centers and hospitals in China have limited experience with PH diagnosis and treatment. Given the potential higher prevalence of PH in China than in the United States and European countries, it is critical to develop suitable, effective, and novel therapeutic approaches for Chinese patients. Measures for the detection and prevention of PH need to be put in place urgently for the management of PH in China.

AB - Significant progress has been made in understanding the pathogenesis of pulmonary hypertension (PH) and developing therapeutic approaches for PH in recent years. Most of the currently available data regarding the prevalence, diagnosis, treatment, and prognosis of PH are from American and European populations. Whether these data are also valid in the Chinese population is still controversial. China has a relatively large population of patients with PH for clinical and basic research. However, many medical centers and hospitals in China have limited experience with PH diagnosis and treatment. Given the potential higher prevalence of PH in China than in the United States and European countries, it is critical to develop suitable, effective, and novel therapeutic approaches for Chinese patients. Measures for the detection and prevention of PH need to be put in place urgently for the management of PH in China.

UR - http://www.scopus.com/inward/record.url?scp=77953314041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953314041&partnerID=8YFLogxK

U2 - 10.1378/chest.09-2802

DO - 10.1378/chest.09-2802

M3 - Article

C2 - 20522582

AN - SCOPUS:77953314041

VL - 137

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6 SUPPL.

ER -